Indication
Malignant Rhabdoid Tumor
6 clinical trials
7 products
2 drugs
Product
TazemetostatClinical trial
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T CellsStatus: Not yet recruiting, Estimated PCD: 2028-02-01
Product
21.15.GPC3-CAR T cellsClinical trial
Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Product
NivolumabProduct
IpilimumabClinical trial
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
CARE T cellsDrug
cyclophosphamideDrug
fludarabineClinical trial
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)Status: Recruiting, Estimated PCD: 2025-01-01
Product
CATCH T cellsClinical trial
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children With Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-01
Product
AGAR T